Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 6, 2017, Pages 580.e1-580.e9

  Iversen, Lisa ^a   Sivasubramaniam, Selvaraj ^a   Lee, Amanda J ^a   Fielding, Shona ^a   Hannaford, Philip C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

cancer; cohort study; oral contraception

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EXPOSURE; ENDOMETRIUM CANCER; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; ORAL CONTRACEPTIVE USE; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; SMOKING; UTERINE CERVIX CANCER; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; FOLLOW UP; HEMATOLOGIC NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS; RISK FACTOR; TIME FACTOR; UNITED KINGDOM; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SMOKING; TIME FACTORS; UNITED KINGDOM; UTERINE CERVICAL NEOPLASMS;

EID: 85015819303     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.02.002     Document Type: Article

References (29)

1. Marks, L.V., Sexual chemistry: a history of the contraceptive pill. 2001, Yale University Press, London.
2. United Nations Department of Economic and Social Affairs Population Division. World contraceptive patterns 2013. 2013, United Nations, New York.
3. International Agency for Research on Cancer & World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/age-specific_table_sel.aspx. Accessed May 6, 2015.
4. IARC Monographs on the Evaluation and Carcinogenic Risks to Man. Volume 100A Pharmaceuticals. A review of human carcinogens, 2012, International Agency for Research on Cancer, Lyon, France, 283–311.
5. Royal College of General Practitioners. Oral contraceptives and health. 1974, Pitman Medical, London.
6. General Registrar's Office. Classification of occupations, 1966. 1966, Her Majesty's Stationery Office, London, UK.
7. World Health Organization. International classification of disease, injuries and causes of death, 8th revision. 1967, WHO, Geneva.
8. Hannaford, P.C., Selvaraj, S., Elliott, A.M., Angus, V., Iversen, L., Lee, A.J., Cancer risk among oral contraceptive users: cohort data from the Royal College of General Practitioner's Oral Contraception Study. BMJ, 335, 2007, 651.
9. Beral, V., Hermon, C., Kay, C., Hannaford, P.C., Darby, S., Reeves, G., Mortality in relation to method of follow-up in the Royal College of General Practitioners’ Oral Contraception Study. Hannaford, P.C., Webb, A.M.C., (eds.) Evidence-guided prescribing of the pill, 1996, Parthenon Publishing Group, London, 327–339.
10. Beral, V., Hermon, C., Kay, C., Hannaford, P., Darby, S., Reeves, G., Mortality associated with oral contraceptives: 25 year follow of cohort of 46,000 women from the Royal College of General Practitioners’ Oral Contraception Study. BMJ 318 (1999), 96–100.
11. Cancer Research UK. Female age-specific incidence rates of all cancers excluding non-melanoma skin cancer C00-97 Excl. C44): 2011-2013. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-Zero. Accessed August 3, 2016.
12. Owen-Smith, V., Hannaford, P.C., Warskyj, M., Ferry, S., Kay, C.R., Effects of changes in smoking status on risk estimates for myocardial infarction among women recruited for the Royal College of General Practitioners’ Oral Contraception Study in the UK. J Epidemiol Community Health 52 (1998), 420–424.
13. Moorhead, T., Hannaford, P., Warskyj, M., Prevalence and characteristics associated with use of hormone replacement therapy in Britain. BJOG 104 (1997), 290–297.
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (1997), 1047–1059.
15. Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385 (2015), 1835–1842.
16. American College of Obstetricians and Gynecologists. Tamoxifen and uterine cancer. Committee Opinion No. 601. Obstet Gynecol 123 (2014), 1394–1397.
17. Weiderpass, E., Adami, H.-O., Baron, J.A., Magnusson, C., Lindgren, A., Persson, I., Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10 (1999), 277–284.
18. Ness, R.B., Grisso, J.A., Klapper, J., et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use of characteristics of oral contraceptives. Am J Epidemiol 152 (2000), 231–241.
19. Royar, J., Becher, H., Chang-Claude, J., Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95 (2001), 370–374.
20. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371 (2008), 303–314.
21. Collaborative Group on Epidemiological Studies of Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27,276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 16 (2015), 1061–1070.
22. Marchbanks, P.A., Curtis, K.M., Mandel, M.G., et al. Oral contraceptive formulation and risk of breast cancer. Contraception 85 (2012), 342–350.
23. Beaber, E.F., Buist, D.S.M., Barlow, W.E., et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Prev Epidemiol 74 (2014), 4078–4089.
24. Lidegaard, O., Nielson, L., Skovlund, C.W., Lokkegaard, E., Venous thrombosis in users of nonoral hormonal contraception: follow-up study, Denmark 2001-10. BMJ, 344, 2012, e2990.
25. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996), 1713–1727.
26. Gierisch, J.M., Coeytaux, R.R., Peragallo Urrutia, R., et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 22 (2013), 1931–1934.
27. Vessey, M., Yeates, D., Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 88 (2013), 678–683.
28. Charlton, B.M., Rich-Edwards, J.W., Colditz, G.A., et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurse’ Health Study: prospective cohort study. BMJ, 349, 2014, g6356.
29. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370 (2007), 1609–1621.